Scarcity has driven up the value of priority review vouchers with AbbVie Inc. agreeing to buy one from United Therapeutics Corp. for a record-setting $350m, meaning the company is paying $87.5m more for each of the four months the voucher will knock off a standard review – which itself is a significant increase over the $67.5m Sanofi paid for the voucher it just redeemed.
Announced Aug. 19 by United Therapeutics, which obtained the rare pediatric disease priority review voucher in March with the approval...